Net Income (Loss) Attributable to Parent in USD of PLUS THERAPEUTICS, INC. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
PLUS THERAPEUTICS, INC. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • PLUS THERAPEUTICS, INC. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$4.42M, a 53.9% decline year-over-year.
  • PLUS THERAPEUTICS, INC. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$20.6M, a 59.7% decline year-over-year.
  • PLUS THERAPEUTICS, INC. annual Net Income (Loss) Attributable to Parent for 2024 was -$13M, a 2.54% increase from 2023.
  • PLUS THERAPEUTICS, INC. annual Net Income (Loss) Attributable to Parent for 2023 was -$13.3M, a 34.3% increase from 2022.
  • PLUS THERAPEUTICS, INC. annual Net Income (Loss) Attributable to Parent for 2022 was -$20.3M, a 51.3% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

PLUS THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$20.6M -$4.42M -$1.55M -53.9% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025
Q2 2025 -$19M $5.15M +$8.09M 01 Apr 2025 30 Jun 2025 10-Q 30 Oct 2025
Q1 2025 -$27.1M -$17.4M -$14.1M -434% 01 Jan 2025 31 Mar 2025 10-Q 30 Oct 2025
Q4 2024 -$13M -$3.9M -$93K -2.44% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 -$12.9M -$2.87M +$345K +10.7% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025
Q2 2024 -$13.2M -$2.94M -$1.46M -98.4% 01 Apr 2024 30 Jun 2024 10-Q 30 Oct 2025
Q1 2024 -$11.8M -$3.26M +$1.54M +32.1% 01 Jan 2024 31 Mar 2024 10-Q 30 Oct 2025
Q4 2023 -$13.3M -$3.81M +$1.85M +32.7% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 -$15.2M -$3.22M +$2M +38.3% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$17.2M -$1.48M +$3.8M +71.9% 01 Apr 2023 30 Jun 2023 10-Q 14 Nov 2024
Q1 2023 -$21M -$4.81M -$689K -16.7% 01 Jan 2023 31 Mar 2023 10-Q 14 Nov 2024
Q4 2022 -$20.3M -$5.66M -$1.5M -36.2% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024
Q3 2022 -$18.8M -$5.22M -$1.5M -40.1% 01 Jul 2022 30 Sep 2022 10-Q 31 Oct 2023
Q2 2022 -$17.3M -$5.28M -$2.48M -88.6% 01 Apr 2022 30 Jun 2022 10-Q 31 Oct 2023
Q1 2022 -$14.8M -$4.12M -$1.4M -51.3% 01 Jan 2022 31 Mar 2022 10-Q 31 Oct 2023
Q4 2021 -$13.4M -$4.16M -$568K -15.8% 01 Oct 2021 31 Dec 2021 10-K 23 Feb 2023
Q3 2021 -$12.8M -$3.72M -$2M -116% 01 Jul 2021 30 Sep 2021 10-Q 20 Oct 2022
Q2 2021 -$10.8M -$2.8M -$961K -52.3% 01 Apr 2021 30 Jun 2021 10-Q 20 Oct 2022
Q1 2021 -$9.87M -$2.72M -$1.63M -150% 01 Jan 2021 31 Mar 2021 10-Q 20 Oct 2022
Q4 2020 -$8.24M -$3.59M -$4.47M -506% 01 Oct 2020 31 Dec 2020 10-K 24 Feb 2022
Q3 2020 -$3.77M -$1.73M -$2.25M -429% 01 Jul 2020 30 Sep 2020 10-Q 21 Oct 2021
Q2 2020 -$1.52M -$1.84M +$7.31M +79.9% 01 Apr 2020 30 Jun 2020 10-Q 21 Oct 2021
Q1 2020 -$8.82M -$1.09M +$2.06M +65.5% 01 Jan 2020 31 Mar 2020 10-Q 21 Oct 2021
Q4 2019 -$10.9M $884K +$3.12M 01 Oct 2019 31 Dec 2019 10-K 22 Feb 2021
Q3 2019 -$14M $526K +$2.86M 01 Jul 2019 30 Sep 2019 10-Q 22 Oct 2020
Q2 2019 -$16.9M -$9.15M -$5.49M -150% 01 Apr 2019 30 Jun 2019 10-Q 22 Oct 2020
Q1 2019 -$11.4M -$3.15M +$1.26M +28.6% 01 Jan 2019 31 Mar 2019 10-Q 22 Oct 2020
Q4 2018 -$12.6M -$2.24M +$2.05M +47.8% 01 Oct 2018 31 Dec 2018 10-K 30 Mar 2020
Q3 2018 -$14.7M -$2.33M +$2.48M +51.5% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019
Q2 2018 -$17.2M -$3.66M +$2.39M +39.5% 01 Apr 2018 30 Jun 2018 10-Q 14 Nov 2019
Q1 2018 -$19.6M -$4.41M +$3.14M +41.6% 01 Jan 2018 31 Mar 2018 10-Q 14 Nov 2019
Q4 2017 -$22.7M -$4.29M +$632K +12.9% 01 Oct 2017 31 Dec 2017 10-K 09 Mar 2018
Q3 2017 -$23.3M -$4.81M +$577K +10.7% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$23.9M -$6.05M +$356K +5.56% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018
Q1 2017 -$24.3M -$7.54M -$2.21M -41.3% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018
Q4 2016 -$22M -$4.92M -$2.16M -78.4% 01 Oct 2016 31 Dec 2016 10-K 09 Mar 2018
Q3 2016 -$19.9M -$5.38M -$6.9M -454% 01 Jul 2016 30 Sep 2016 10-K 09 Mar 2018
Q2 2016 -$13M -$6.41M -$10.9M -244% 01 Apr 2016 30 Jun 2016 10-K 09 Mar 2018
Q1 2016 -$2.13M -$5.34M +$16.6M +75.7% 01 Jan 2016 31 Mar 2016 10-K 09 Mar 2018
Q4 2015 -$18.7M -$2.76M +$3M +52.1% 01 Oct 2015 31 Dec 2015 10-K 24 Mar 2017
Q3 2015 -$21.7M $1.52M +$10.9M 01 Jul 2015 30 Sep 2015 10-K 24 Mar 2017
Q2 2015 -$32.6M $4.45M +$16.3M 01 Apr 2015 30 Jun 2015 10-K 24 Mar 2017
Q1 2015 -$48.9M -$22M -$11.6M -111% 01 Jan 2015 31 Mar 2015 10-K 24 Mar 2017
Q4 2014 -$37.4M -$5.76M +$4.29M +42.7% 01 Oct 2014 31 Dec 2014 10-K 11 Mar 2016
Q3 2014 -$41.7M -$9.39M -$4.13M -78.5% 01 Jul 2014 30 Sep 2014 10-K 11 Mar 2016
Q2 2014 -$37.5M -$11.8M -$8.62M -268% 01 Apr 2014 30 Jun 2014 10-K 11 Mar 2016
Q1 2014 -$28.9M -$10.4M -$2.73M -35.6% 01 Jan 2014 31 Mar 2014 10-K 11 Mar 2016
Q4 2013 -$26.2M -$10M -$6.22M -163% 01 Oct 2013 31 Dec 2013 10-K 16 Mar 2015
Q3 2013 -$20M -$5.26M +$5.99M +53.3% 01 Jul 2013 30 Sep 2013 10-K 16 Mar 2015
Q2 2013 -$25.9M -$3.21M +$4.67M +59.3% 01 Apr 2013 30 Jun 2013 10-K 16 Mar 2015
Q1 2013 -$30.6M -$7.67M +$1.66M +17.8% 01 Jan 2013 31 Mar 2013 10-K 16 Mar 2015
Q4 2012 -$32.3M -$3.82M +$3.08M +44.6% 01 Oct 2012 31 Dec 2012 10-K 14 Mar 2014
Q3 2012 -$35.4M -$11.2M -$2.91M -34.9% 01 Jul 2012 30 Sep 2012 10-K 14 Mar 2014
Q2 2012 -$32.4M -$7.88M -$2.75M -53.4% 01 Apr 2012 30 Jun 2012 10-K 14 Mar 2014
Q1 2012 -$29.7M -$9.33M +$2.75M +22.8% 01 Jan 2012 31 Mar 2012 10-K 14 Mar 2014
Q4 2011 -$32.5M -$6.91M 01 Oct 2011 31 Dec 2011 10-K 15 Mar 2013
Q3 2011 -$8.34M +$2.08M +20% 01 Jul 2011 30 Sep 2011 10-K 15 Mar 2013
Q2 2011 -$5.14M +$239K +4.45% 01 Apr 2011 30 Jun 2011 10-K 15 Mar 2013
Q1 2011 -$12.1M 01 Jan 2011 31 Mar 2011 10-K 15 Mar 2013
Q3 2010 -$10.4M 01 Jul 2010 30 Sep 2010 10-Q 08 Nov 2011
Q2 2010 -$5.38M 01 Apr 2010 30 Jun 2010 10-Q 09 Aug 2011

PLUS THERAPEUTICS, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$13M +$338K +2.54% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 -$13.3M +$6.96M +34.3% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 -$20.3M -$6.88M -51.3% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024
2021 -$13.4M -$5.16M -62.6% 01 Jan 2021 31 Dec 2021 10-K 23 Feb 2023
2020 -$8.24M +$2.65M +24.3% 01 Jan 2020 31 Dec 2020 10-K 24 Feb 2022
2019 -$10.9M +$1.75M +13.8% 01 Jan 2019 31 Dec 2019 10-K 22 Feb 2021
2018 -$12.6M +$10.1M +44.3% 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2020
2017 -$22.7M -$640K -2.9% 01 Jan 2017 31 Dec 2017 8-K 10 Sep 2019
2016 -$22M -$3.3M -17.6% 01 Jan 2016 31 Dec 2016 10-K 09 Mar 2018
2015 -$18.7M +$18.6M +49.8% 01 Jan 2015 31 Dec 2015 10-K 24 Mar 2017
2014 -$37.4M -$11.2M -42.8% 01 Jan 2014 31 Dec 2014 10-K 11 Mar 2016
2013 -$26.2M +$6.1M +18.9% 01 Jan 2013 31 Dec 2013 10-K 11 Mar 2016
2012 -$32.3M +$172K +0.53% 01 Jan 2012 31 Dec 2012 10-K 16 Mar 2015
2011 -$32.5M -$4.96M -18% 01 Jan 2011 31 Dec 2011 10-K 14 Mar 2014
2010 -$27.5M 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.